Biogen
BIIB
1,001 hedge funds and large institutions have $35B invested in Biogen in 2023 Q1 according to their latest regulatory filings, with 89 funds opening new positions, 342 increasing their positions, 364 reducing their positions, and 101 closing their positions.
11% more call options, than puts
Call options by funds: $748M | Put options by funds: $674M
1.79% more ownership
Funds ownership: 86.72% → 88.51% (+1.8%)
2% more capital invested
Capital invested by funds: $34.2B → $35B (+$767M)
6% less repeat investments, than reductions
Existing positions increased: 342 | Existing positions reduced: 364
3% less funds holding
Funds holding: 1,031 → 1,001 (-30)
12% less first-time investments, than exits
New positions opened: 89 | Existing positions closed: 101
24% less funds holding in top 10
Funds holding in top 10: 25 → 19 (-6)
Top Buyers
Top Sellers
| 1 |
Marshall Wace
London,
United Kingdom
|
-$197M |
| 2 |
Man Group
London,
United Kingdom
|
-$192M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$147M |
| 4 |
Two Sigma Advisers
New York
|
-$139M |
| 5 |
D.E. Shaw & Co
New York
|
-$117M |
BIIB Hedge Fund Activity: Q1 2023 in Review
1,001 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2023, worth a combined $35B — up 2.2% from $34.2B a quarter earlier.
Sellers outnumbered buyers: 101 funds closed out of BIIB and 89 opened new positions — a net loss of 12 holders — while 364 trimmed existing stakes and 342 added.
The largest buyer was Envestnet Asset Management, adding an estimated $626M. The largest seller was Marshall Wace, cutting an estimated $197M.
- 1,001 institutional investors held Biogen (BIIB) as of Q1 2023, down from 1,031 in Q4 2022.
- Funds reported $35B of Biogen stock for Q1 2023, up 2.2% quarter-over-quarter.
- 89 funds opened new Biogen positions in Q1 2023 and 101 closed out, a net change of -12 holders.
- The largest Biogen buyer in Q1 2023 was Envestnet Asset Management, an estimated $626M added.
- The largest Biogen seller in Q1 2023 was Marshall Wace, an estimated $197M sold.
Based on aggregated 13F filings for Q1 2023.